Featured Research

from universities, journals, and other organizations

Rare skin cancer vaccine: Early stage research begins

Date:
November 5, 2010
Source:
Yorkshire Cancer Research
Summary:
Scientists plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel cell carcinoma cancers. They will use these synthetic MCC cancer cells along with real MCC cell patient samples to analyze the reactions of human immune cells against them. The scientists ultimately hope to increase current knowledge about the human body’s ability to eliminate MCC cancer cells to help develop a vaccine in the future.

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

Related Articles


Researchers at the University of Leeds have taken their first steps towards understanding why a rare skin cancer that is rapidly growing in incidence in Europe and the USA is not recognised by the body's immune system.

Merkel cell carcinoma (MCC) arises from uncontrolled growth of skin cells and usually develops on sun-exposed areas as a firm, painless, red-coloured bump that grows over several weeks to months.

The condition typically develops in people aged 65 and over and those with weakened immune systems and there are currently around 1500 cases a year in the UK with one third of these proving fatal.

During recent research, around 80 percent of MCCs on human skin were shown to contain a virus termed Merkel cell polyomavirus which is believed to be associated with the growth of this cancer.

Now Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of this virus into normal human skin cells to produce skin cells that have features of MCC cancers.

They will use these synthetic MCC cancer cells along with real MCC cell patient samples to analyse the reactions of human immune cells against them.

The scientists ultimately hope to increase current knowledge about the human body's ability to eliminate MCC cancer cells to help develop a vaccine in the future.

Professor Eric Blair, who is leading the project, said: "Since a virus is involved in the development of Merkel cell carcinoma skin cancer it is important to understand how the virus prevents the immune system attacking the MCC tumour.

"We are aiming to develop strategies to prevent or eradicate tumours and improve the prognosis of patients who suffer with this terrible skin disease which is currently extremely poor."


Story Source:

The above story is based on materials provided by Yorkshire Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

Yorkshire Cancer Research. "Rare skin cancer vaccine: Early stage research begins." ScienceDaily. ScienceDaily, 5 November 2010. <www.sciencedaily.com/releases/2010/11/101105085423.htm>.
Yorkshire Cancer Research. (2010, November 5). Rare skin cancer vaccine: Early stage research begins. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2010/11/101105085423.htm
Yorkshire Cancer Research. "Rare skin cancer vaccine: Early stage research begins." ScienceDaily. www.sciencedaily.com/releases/2010/11/101105085423.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins